Metabolic effects of prazosin.
The effects of oral administration of 2 mg prazosin on several metabolic and endocrine variables were evaluated in 12 patients with hypertension (6 with normal and 6 with abnormal glucose tolerance). Prazosin was followed by a rise in plasma glucose and serum free fatty acids (FFA) in both normal and diabetic subjects; there was a trend upward in serum albumin (IRI), but growth hormone (GH), prolactin (PRL), and gastrin did not change. Although these results are in general agreement with metabolic effects of other alpha adrenergic blockers already reported, the rise in plasma glucose is at variance with studies performed with phentolamine.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005755:Gastrins / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006728:Hormones / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D011224:Prazosin / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood; D011799:Quinazolines / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D005755:Gastrins; D006728:Hormones; D007328:Insulin; D011799:Quinazolines; D011388:Prolactin; D013006:Growth Hormone; D011224:Prazosin